EP
PHVS icon

Eversept Partners’s Pharvaris PHVS Stock Holding History

Eversept Partners’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5M Sell
406,960
-32,217
-7% -$860K 0.61% 41
2025
Q4 		$12.2M Buy
+439,177
New +$10.6M 0.61% 43

Other funds holding PHVS

GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EFM
EQT Fund Management Luxembourg $1.02B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Eversept Partners's PHVS Position: Q1 2026 in Review

Eversept Partners reduced its Pharvaris (PHVS) stake by 7.3% in Q1 2026, selling an estimated $860K and leaving 406,960 shares worth $11.5M. The position accounts for 0.61% of the portfolio, ranked #41.

Eversept Partners first reported a position in PHVS in Q4 2025 and has held it in 2 quarters since. The position peaked at $12.2M in Q4 2025. 110 funds tracked by Wall St. Rank hold PHVS as of Q1 2026.

  • Eversept Partners held 406,960 shares of Pharvaris worth $11.5M as of Q1 2026.
  • Eversept Partners sold 32,217 Pharvaris shares in Q1 2026, an estimated $860K.
  • Pharvaris made up 0.61% of Eversept Partners's portfolio in Q1 2026, its #41 holding.
  • Eversept Partners first reported a position in Pharvaris in Q4 2025 and has held it in 2 quarters since.
  • Eversept Partners's Pharvaris position peaked at $12.2M in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Pharvaris as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.